Boehringer Ingelheim's Pradaxa to garner bigger sales in Korea

Published: 2011-02-22 06:59:00

Updated: 2011-02-22 06:59:00

Pradaxa (dabigatran etexilate), which was approved by the Korea Food and Drug Administration on February 18, will hit the domestic blood thinning products market, according to market experts.

Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK